page_title: RECOVERY Trial
section_title: Dexamethasone
hierarchical_section_title: RECOVERY Trial / Results / Dexamethasone
caption_attribution_description: English: The image shows the mortality rates for 1007 COVID-19 patients on mechanical ventilation at time of randomisation: 324 patients who received Dexamethasone (in Red) compared to 683 who received standard hospital care (in Black)
context_page_description: The Randomised Evaluation of COVID-19 therapy Trial is a large-enrollment clinical trial of possible treatments for people in the United Kingdom admitted to hospital with severe COVID-19 infection. As of 17 June 2020, the trial included six proposed interventions: five repurposed drugs and convalescent plasma.
context_section_description: On 22 June 2020, preliminary results were published in a preprint showing that low-dose dexamethasone treatment reduced the death rate by one third in hospitalized people needing ventilators due to severe COVID-19 infection, and by one fifth in people treated with oxygen therapy. There was no benefit (and the possibility of harm) among people who did not require oxygen. The preliminary report was subsequently published in The New England Journal of Medicine.
caption: Mortality rates over 28 days for 1007 COVID-19 patients on mechanical ventilation at time of randomisation: 324 patients who received dexamethasone (red) compared to 683 who received standard hospital care (black)[10]
exif: {"Image ExifOffset": "2140", "Image Padding": "[]", "EXIF Padding": "[]"}